Abstract 1878P
Background
The growing number of patients with genitourinary cancers (GU) could create an increasing burden on GU oncologists. Bureau for Cancer Research (BUCARE) describes the prevalence of burnout in GU oncologists in Central Asia region.
Methods
This is a cross-sectional survey study conducted among practicing cancer care physicians (surgical, medical, radiation) at the ASCO / Asian American GU Symposium ( Almaty, April 2023 ). The primary outcome was burnout experience assessed through the Maslach Burnout Inventory.
Results
A total of 101 oncologists completed the questionnaire. Table summarizes physician's characteristics. Despite the fact that 100% of responders are interested in their work, 66% (67 of 101) had symptoms of burnout (high emotional exhaustion and/or depersonalization scores). Fifty percent of oncologists are ready to turn to a psychologist for help. Significant drivers of burnout identified in multivariable regression modeling included ³20 patients per day (odds ratio [OR] = 14.8; P<0.001) and ³10 working hours per day (OR=8.6; P<0.001). Male gender (OR=0.14; P<0.001) and specialization in radiation therapy (OR=0.20; P<0.01) were associated with lower odds of burnout.
Conclusions
More than half of participants met predefined standardized criteria for burnout. Expanding the staff of GU oncologists and reducing the daily workload may improve the emotional state of physicians. Table: 1878P
Characteristics | N=101 |
Gender, N (%) | |
Female | 68 (67.3) |
Male | 33 (37.7) |
Region, N (%) | |
Kazakhstan | 85 (84.2) |
Other countries | 17 (16.8) |
Specialty, N (%) | |
Surgery | 39 (38.6) |
Medical Oncology | 44 (43.6) |
Radiation Oncology | 18 (17.8) |
Department, N (%) | |
In-patient | 79 (78.2) |
Out-patient | 22 (21.8) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05